Background: Human Papillomaviruses (HPVs) cause several epithelial cancers as well as a range of benign lesions. Cervical cancer is the most serious cancer worldwide attributable to HPV infection, as it accounts for almost 10% of all cancer in women and is the most common female cancer in many developing countries. In the US, the incidence of HPV-positive “non-cervical” cancers, which include anal, vulvar vaginal, penile, and oropharyngeal cancer, is similar to that of cervical cancer. More than 10 HPV types have been shown to be oncogenic, although HPV16 and HPV18 (HPV16/18) together account for about 70% of the cervical cancers and an even higher proportion of the non-cervical cancers. There are two FDA-approved sub-unit HPV vaccines, both of which are based on the ability of the major L1 capsid protein of HPVs to self-assemble into virus-like particles (VLPs), which are highly immunogenic. The main protective activity of the vaccines is their induction of neutralizing antibodies, which are HPV type-restricted. A full course of vaccination involves 3 doses over a 6 month period. The vaccines are highly effective against the HPV types they target (vaccine types), but have more limited activity against non-vaccine types. Two important goals of second generation HPV vaccines are to safely reduce the number of doses required to induce long-term protection, and to increase the number of HPV types efficiently protected by HPV vaccination. Conclusions: The presentation will focus on research efforts to accomplish these goals.